ROCK SPRINGS CAPITAL MANAGEMENT LP
Q2 2023 Form 13-F
BALTIMORE, MARYLAND
CIK 0001595725
· CRD 168648
· SEC-registered investment adviser
$4.2B Reported Value Total
ROCK SPRINGS CAPITAL reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $5,716,429,633, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-24
Reported value
$4.2B
Quarter over quarter
+4.1%
Holdings
119
Top-10 concentration
34.3%
Key People
Form ADV owners & control persons
Gordon Margraf ("mark") Bussard
MEMBER/LIMITED PARTNER
Kris Harlan Jenner
MEMBER/LIMITED PARTNER
Nnamdi C Etoh
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $4.2B |
| Positions | 119 |
| Change in reported value | +0.3% |
| New positions | 7 |
| Exited positions | 4 |
| Position turnover | 8.9% |
| Top-10 concentration | 34.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
104 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
100 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
97 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
91 | $1.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
92 | $1.6B |
|
Q1 2025 13F
Filed May 15, 2025
|
95 | $1.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
105 | $2.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
107 | $3.1B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
107 | $3.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
109 | $3.9B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
99 | $4.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
116 | $3.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
119 | $4.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
116 | $4.2B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
116 | $4.2B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
123 | $3.9B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
125 | $3.4B |
|
Q1 2022 13F
Filed May 16, 2022
|
128 | $4.0B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
128 | $4.3B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
145 | $4.8B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | HUM HUMANA INC | $210.2M | 5.0% |
| 2 | IMCR IMMUNOCORE HLDGS PLC | $181.6M | 4.32% |
| 3 | PODD INSULET CORP | $161.2M | 3.83% |
| 4 | AGL AGILON HEALTH INC | $143.6M | 3.42% |
| 5 | BPMC BLUEPRINT MEDICINES CORP | $138.2M | 3.29% |
| 6 | ARGX ARGENX SE | $136.4M | 3.25% |
| 7 | PEN PENUMBRA INC | $125.9M | 3.0% |
| 8 | NBIX NEUROCRINE BIOSCIENCES INC | $120.7M | 2.87% |
| 9 | EVH EVOLENT HEALTH INC | $115.2M | 2.74% |
| 10 | UNH UNITEDHEALTH GROUP INC | $110.5M | 2.63% |
| 11 | KRTX KARUNA THERAPEUTICS INC | $107.0M | 2.55% |
| 12 | ISRG INTUITIVE SURGICAL INC | $102.1M | 2.43% |
| 13 | IDXX IDEXX LABS INC | $97.7M | 2.32% |
| 14 | EXAS EXACT SCIENCES CORP | $88.6M | 2.11% |
| 15 | CERE CEREVEL THERAPEUTICS HLDNG I | $79.9M | 1.9% |
| 16 | WST WEST PHARMACEUTICAL SVSC INC | $77.3M | 1.84% |
| 17 | SGEN SEAGEN INC | $77.0M | 1.83% |
| 18 | ALGN ALIGN TECHNOLOGY INC | $76.7M | 1.83% |
| 19 | AGIO AGIOS PHARMACEUTICALS INC | $76.1M | 1.81% |
| 20 | AKRO AKERO THERAPEUTICS INC | $72.4M | 1.72% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.